Genetic modeling of ovarian phenotypes in mice for the study of human polycystic ovary syndrome

American Journal of Translational Research

Volumn 5, Issue 1, 2013, Pages 15-20

  Feng, Yi ^a,b   Li, Xin ^c   Shao, Ruijin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b FUDAN UNIVERSITY   (China)

^c OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Hemorrhagic cystic follicles; PCOS; Transgenic and knockout mice

Indexed keywords

ANDROGEN; CHORIONIC GONADOTROPIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN; LUTEINIZING HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERIC GONADOTROPIN;

GENE EXPRESSION; GENETIC MODEL; HUMAN; HYPERPLASIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHENOTYPE; REVIEW; THECA CELL; TRANSGENIC MOUSE;

ANIMALIA; MUS;

EID: 84872815380     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ and Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551.
3. Norman RJ, Dewailly D, Legro RS and Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.
4. Jansen E, Laven JS, Dommerholt HB, Polman J, van Rijt C, van den Hurk C, Westland J, Mossel- man S and Fauser BC. Abnormal gene expres- sion profles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol 2004; 18: 3050-3063.
5. Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, Mosselman S and Strauss JF 3rd. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defned by mi- croarray analysis. J Biol Chem 2003; 278: 26380-26390.
6. Franks S, Stark J and Hardy K. Follicle dynam- ics and anovulation in polycystic ovary syn- drome. Hum Reprod Update 2008; 14: 367-378.
7. Hall JE, Taylor AE, Hayes FJ and Crowley WF Jr. Insights into hypothalamic-pituitary dysfunc- tion in polycystic ovary syndrome. J Endocrinol Invest 1998; 21: 602-611.
8. Jakimiuk AJ, Weitsman SR, Navab A and Ma- goffn DA. Luteinizing hormone receptor, ste- roidogenesis acute regulatory protein, and ste- roidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granu- losa cells from polycystic ovaries. J Clin Endo- crinol Metab 2001; 86: 1318-1323.
9. Dunaif A and Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001; 52: 401-419.
10. Nemade RV, Carrette O, Larsen WJ and Mar-koff E. Involvement of nitric oxide and the ovar- ian blood follicle barrier in murine follicular cyst development. Fertil Steril 2002; 78: 1301-1308.
11. Matzuk MM, DeMayo FJ, Hadsell LA and Kumar TR. Overexpression of human chorionic gonad- otropin causes multiple reproductive defects in transgenic mice. Biol Reprod 2003; 69: 338-346.
12. Risma KA, Clay CM, Nett TM, Wagner T, Yun J and Nilson JH. Targeted overexpression of lu- teinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tu- mors. Proc Natl Acad Sci U S A 1995; 92: 1322-1326.
13. Risma KA, Hirshfeld AN and Nilson JH. Elevat- ed luteinizing hormone in prepubertal trans- genic mice causes hyperandrogenemia, preco- cious puberty, and substantial ovarian pathology. Endocrinology 1997; 138: 3540-3547.
14. Meehan TP, Harmon BG, Overcast ME, Yu KK, Camper SA, Puett D and Narayan P. Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chori- onic gonadotropin-lutropin receptor complex. J Mol Endocrinol 2005; 34: 489-503.
15. Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M and Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic fe- male mice producing high levels of human chorionic gonadotropin. Endocrinology 2002; 143: 4084-4095.
16. Kumar TR, Wang Y, Lu N and Matzuk MM. Fol- licle stimulating hormone is required for ovari- an follicle maturation but not male fertility. Nat Genet 1997; 15: 201-204.
17. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC and Matzuk MM. Transgen- ic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 1999; 13: 851-865.
18. Azziz R, Carmina E, Dewailly D, Diamanti-Kan-darakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE and Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fer- til Steril 2009; 91: 456-488.
19. Adams JM, Taylor AE, Crowley WF Jr and Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysi- ology of polycystic ovarian syndrome. J Clin En- docrinol Metab 2004; 89: 4343-4350.
20. Brawer JR, Naftolin F, Martin J and Sonnen-schein C. Effects of a single injection of estra- diol valerate on the hypothalamic arcuate nu- cleus and on reproductive function in the female rat. Endocrinology 1978; 103: 501-512.
21. Brawer JR, Munoz M and Farookhi R. Develop- ment of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol Re- prod 1986; 35: 647-655.
22. Lee MT, Anderson E and Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandros- terone. Anat Rec 1991; 231: 185-192.
23. Manneras L, Cajander S, Holmang A, Seles-kovic Z, Lystig T, Lonn M and Stener-Victorin E. A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome. Endocrinology 2007; 148: 3781-3791.
24. Kaipia A and Hsueh AJ. Regulation of ovarian follicle atresia. Annu Rev Physiol 1997; 59: 349-363.
25. Leung PC, Goldenberg SR and Armstrong DT. Changes with age in aromatization of testos- terone in immature female rats. Biol Reprod 1978; 19: 1036-1039.
26. Leung PC and Armstrong DT. Estrogen treat- ment of immature rats inhibits ovarian andro- gen production in vitro. Endocrinology 1979; 104: 1411-1417.
27. Magoffn DA and Erickson GF. Mechanism by which 17 beta-estradiol inhibits ovarian andro- gen production in the rat. Endocrinology 1981; 108: 962-969.
28. Britt KL, Drummond AE, Cox VA, Dyson M, Wr- eford NG, Jones ME, Simpson ER and Findlay JK. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aroma- tase) gene. Endocrinology 2000; 141: 2614-2623.
29. Ito Y, Fisher CR, Conte FA, Grumbach MM and Simpson ER. Molecular basis of aromatase de- fciency in an adult female with sexual infantil- ism and polycystic ovaries. Proc Natl Acad Sci U S A 1993; 90: 11673-11677.
30. Couse JF, Bunch DO, Lindzey J, Schomberg DW and Korach KS. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-al- pha knockout mouse. Endocrinology 1999; 140: 5855-5865.
31. Lee S, Kang DW, Hudgins-Spivey S, Krust A, Lee EY, Koo Y, Cheon Y, Gye MC, Chambon P and Ko C. Theca-specifc Esr1 knockout mice lose fertility prematurely. Endocrinology 2009 Aug; 150: 3855-62.
32. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P and Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000; 127: 4277-4291.
33. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS and Smithies O. Alteration of repro- ductive function but not prenatal sexual devel- opment after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993; 90: 11162-11166.
34. Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE and Korach KS. Targeted disruption of the estrogen receptor- alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 1999; 140: 2733-2744.
35. Devin JK, Johnson JE, Eren M, Gleaves LA, Bradham WS, Bloodworth JR Jr and Vaughan DE. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the develop- ment of polycystic ovarian changes in female mice. J Mol Endocrinol 2007; 39: 9-16.
36. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF 3rd and Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998; 53: 217-256.
37. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB and Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A 2000; 97: 12729-12734.
38. Dissen GA, Lara HE, Leyton V, Paredes A, Hill DF, Costa ME, Martinez-Serrano A and Ojeda SR. Intraovarian excess of nerve growth factor increases androgen secretion and disrupts es- trous cyclicity in the rat. Endocrinology 2000; 141: 1073-1082.
39. Lara HE, Dissen GA, Leyton V, Paredes A, Fuenzalida H, Fiedler JL and Ojeda SR. An in- creased intraovarian synthesis of nerve growth factor and its low affnity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000; 141: 1059-1072.
40. Dissen GA, Garcia-Rudaz C, Paredes A, Mayer C, Mayerhofer A and Ojeda SR. Excessive ovar- ian production of nerve growth factor facili- tates development of cystic ovarian morpholo- gy in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology 2009; 150: 2906-2914.
41. Sampson M, Kong C, Patel A, Unwin R and Ja- cobs HS. Ambulatory blood pressure profles and plasminogen activator inhibitor (PAI-1) ac- tivity in lean women with and without the poly- cystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45: 623-629.
42. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH and Prentice AG. The plasminogen ac- tivator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236-241.
43. Tarkun I, Canturk Z, Arslan BC, Turemen E and Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004; 51: 467-472.
44. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A and Lombardi G. Is plasminogen activator inhibi- tor-1 a cardiovascular risk factor in young wom- en with polycystic ovary syndrome? Reprod Biomed Online 2004; 9: 505-510.
45. Bagos PG. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. Mol Hum Reprod 2009; 15: 19-26.